NeOnc Technologies releases transcript of investor call on NEO100-01 Phase 2a trial results in recurrent IDH1-mutant high-grade glioma

• Neonc Technologies hosted an investor call on Aug. 12, 2026 to discuss Phase 2a top-line results for NEO100-01 in recurrent IDH1-mutant high-grade glioma.
• Attendees included the CEO, CFO, founder and CSO, chief clinical officer, board directors, scientific advisory board members, scientific chair.
• Phase 2a met its primary endpoint, with PFS6 of 48.9% versus a 20% historical benchmark; intent-to-treat population was 24 patients.
• Median overall survival measured from recurrence was 26.09 months versus a 6-9 month salvage-therapy benchmark; OS was 60.9% at 12 months.
• Management outlined an FDA meeting to seek a Phase 3 accelerated-approval path using randomization against lomustine, with OS as the primary endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-008773), on August 13, 2026, and is solely responsible for the information contained therein.